Matinas Biopharma Q4 2022 Earnings Report

Matinas Biopharma EPS Results

• Actual EPS: -$0.02
• Consensus EPS: -$0.02
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Matinas Biopharma Revenue Results

• Actual Revenue: $1.06 million
• Expected Revenue: $1.10 million
• Beat/Miss: Missed by -$40.00 thousand
• YoY Revenue Growth: N/A

Matinas Biopharma Announcement Details

• Quarter: Q4 2022
• Date: 3/15/2023
• Time: N/A

Matinas Biopharma (NYSE:MTNB), a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.